Evonik Evonik

X

Find the latest news about AEGERION aggregated by PharmaCompass.com.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
AEGERION
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
--
Telephone
Telephone
Client Website
Website
--
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390

FDA
31 Mar 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390

FDA
28 Feb 2022

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390

FDA
14 Jun 2021

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390

FDA
16 Jul 2020

https://www.fiercebiotech.com/biotech/amryt-buys-aegerion-via-bankruptcy-adding-sales-to-support-r-d

N.P.Taylor FIERCE BIOTECH
26 Sep 2019

https://endpts.com/coming-out-of-chapter-11-aegerion-jumps-into-welcome-arms-of-irish-pharma-with-big-plans-fresh-60m-for-its-drugs/

Amber Tong ENDPTS
25 Sep 2019

https://www.fiercepharma.com/pharma/most-expensive-meds-u-s-topped-by-novartis-and-spark-gene-therapies

Eric Sagonowsky FIERCE PHARMA
13 Jun 2019

https://pharmaphorum.com/news/amryt-to-expand-rare-disease-portfolio-with-311m-aegerion-merger/

Richard Staines PHARMAPHORUM
23 May 2019

https://www.nasdaq.com/press-release/novelion-therapeutics-announces-subsidiary-aegerion-pharmaceuticals-to-recapitalize-through-court-20190520-00995

NASDAQ
20 May 2019

https://www.fiercepharma.com/pharma/top-20-most-expensive-drugs-2018-featuring-names-big-and-small

Eric Sagonowsky FIERCE PHARMA
29 Dec 2018
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY